What is the market's earnings forecast for Fulgent Genetics next quarter?

Did Fulgent Genetics beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Fulgent Genetics year over year?

What were the key takeaways from Fulgent Genetics’s earnings call?

What factors drove the changes in Fulgent Genetics's revenue and profit?

What guidance did Fulgent Genetics's management provide for the next earnings period?

What is Fulgent Genetics's gross profit margin?

What were the key takeaways from Fulgent Genetics's earnings call?

- **Revenue Growth**: Q3 2025 lab services revenue up 15% YoY to $84.1M, driven by new product launches (ultrarapid WGS, Beacon K). 
- **Therapeutic Pipeline**: FID-007 Phase II shows 44-59% ORR, PFS 7.8M vs. 2.3M control.
- **Financial Health**: Non-GAAP EPS $0.14, gross margin 44.3%, 2025 guidance raised to $325M (+15% YoY). 
- **AI & Digital Pathology**: EZPath IMS deployment enables 48-hour WGS reports, reducing costs by $67.9M in Q3.
- **Shareholder Value**: $139.6M remaining under buyback program; 2025 cash position $787.7M.


**【CEO Summary Section】**
- Q3 2025 revenue reached $84.1 million, up 3.1% sequentially and 15% year-over-year, driven by lab services growth and therapeutic pipeline progress.
- FID-007 Phase II trial shows ORR of 44% and 59% across dose levels, with PFS of 7.8 months vs. 2.3 months for standard care.
- FID-022 Phase I trial completes first dose level, with second dose level initiated.

**【CFO Financial Commentary】**
- Non-GAAP EPS: $0.14 (up from $0.10 in Q2), reflecting $4.5 million net income.
- Gross margin: 44.3% (non-GAAP), up 150 basis points YoY, driven by operational efficiency.
- 2025 guidance raised to $325 million (15% YoY growth), with non-GAAP operating margin improving to -10%.

**【Q&A Highlights】**
- Collections timing resolved, with Q3 collections improving sequentially.
- New products: ultrarapid whole genome sequencing (NICU-focused) and Beacon K (1,000-gene panel) launched.
- Therapeutic development: Phase III for FID-007 expected to begin in 2026 with ~$60 million cost.
- Digital pathology IMS (EZPath) deployment enhances AI-driven workflows.
- 2025 cash position: $787.7 million (up $67.9M YoY), with $139.6M remaining under share buyback program.


Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

FLGT

FLGT fundamentals

You can ask Aime